Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):54–60. doi: 10.1038/bjc.1990.228

Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA.

D R Mans 1, J Retèl 1, J M van Maanen 1, M V Lafleur 1, M A van Schaik 1, H M Pinedo 1, J Lankelma 1
PMCID: PMC1971739  PMID: 2167725

Abstract

The mechanism of action of the anti-tumour agent etoposide (VP-16-213) could involve its bioactivation to metabolites which can damage DNA. Active metabolites of etoposide, generated in vitro, are the 3',4'-dihydroxy-derivative (catechol) and its oxidation product, the ortho-quinone. The conversion of the catechol into the ortho-quinone (and vice versa) proceeds via formation of a semi-quinone free radical. We investigated the role of this radical species in the inactivation of biologically active single- (ss) and double-stranded (RF) phi X174 DNA. Since the formation of semi-quinone free radicals from the ortho-quinone of etoposide is pH dependent, experiments were performed, in which the ortho-quinone was incubated at pH 4, 7.4 and greater than or equal to 9. ESR measurements showed no formation of radical species from the ortho-quinone at pH 4, but an increased rate of generation of the primary semi-quinone free radical at pH values 7.4 to 10; at still higher pH values a secondary semi-quinone free radical was produced. HPLC analyses demonstrated chemical stability of the ortho-quinone at pH 4, but an accelerated decay was observed when the pH was elevated from 7.4 to 9, with its concomitant conversion into more polar components and into the catechol of etoposide. Ss phi X174 DNA, exposed to the ortho-quinone, was inactivated at an increasing rate at pH values increasing from 4 to 7.4 and subsequently to 9. RF phi X174 DNA was only significantly inactivated in incubations with the ortho-quinone at pH 4, not at pH values 7.4 and 9. From these data it is concluded that the primary semi-quinone free radical of etoposide may to a great extent be responsible for the ortho-quinone-induced ss phi X174 DNA inactivation, but that this radical species is not lethal towards RF phi X174 DNA.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baas P. D., Teertstra W. R., van Mansfeld A. D., Jansz H. S., van der Marel G. A., Veeneman G. H., van Boom J. H. Construction of viable and lethal mutations in the origin of bacteriophage 'phi' X174 using synthetic oligodeoxyribonucleotides. J Mol Biol. 1981 Nov 15;152(4):615–639. doi: 10.1016/0022-2836(81)90120-0. [DOI] [PubMed] [Google Scholar]
  2. Blok J., Luthjens L. H., Roos A. L. The radiosensitivity of bacteriophage DNA in aqueous solution. Radiat Res. 1967 Mar;30(3):468–482. [PubMed] [Google Scholar]
  3. Chen G. L., Yang L., Rowe T. C., Halligan B. D., Tewey K. M., Liu L. F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Nov 10;259(21):13560–13566. [PubMed] [Google Scholar]
  4. Glisson B. S., Smallwood S. E., Ross W. E. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta. 1984 Oct 5;783(1):74–79. doi: 10.1016/0167-4781(84)90080-0. [DOI] [PubMed] [Google Scholar]
  5. Haim N., Nemec J., Roman J., Sinha B. K. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res. 1987 Nov 15;47(22):5835–5840. [PubMed] [Google Scholar]
  6. Kalyanaraman B., Nemec J., Sinha B. K. Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR Study. Biochemistry. 1989 May 30;28(11):4839–4846. doi: 10.1021/bi00437a048. [DOI] [PubMed] [Google Scholar]
  7. Loike J. D., Horwitz S. B. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry. 1976 Dec 14;15(25):5443–5448. doi: 10.1021/bi00670a004. [DOI] [PubMed] [Google Scholar]
  8. Long B. H., Musial S. T., Brattain M. G. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry. 1984 Mar 13;23(6):1183–1188. doi: 10.1021/bi00301a024. [DOI] [PubMed] [Google Scholar]
  9. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther. 1987;35(1-2):57–162. doi: 10.1016/0163-7258(87)90105-7. [DOI] [PubMed] [Google Scholar]
  10. Ross W., Rowe T., Glisson B., Yalowich J., Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec;44(12 Pt 1):5857–5860. [PubMed] [Google Scholar]
  11. Sinha B. K., Eliot H. M., Kalayanaraman B. Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett. 1988 Jan 25;227(2):240–244. doi: 10.1016/0014-5793(88)80906-2. [DOI] [PubMed] [Google Scholar]
  12. Sinha B. K., Myers C. E. Irreversible binding of etoposide (VP-16-213) to deoxyribonucleic acid and proteins. Biochem Pharmacol. 1984 Nov 15;33(22):3725–3728. doi: 10.1016/0006-2952(84)90166-7. [DOI] [PubMed] [Google Scholar]
  13. Smith P. J., Anderson C. O., Watson J. V. Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Res. 1986 Nov;46(11):5641–5645. [PubMed] [Google Scholar]
  14. Stähelin H. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer. 1973 Mar;9(3):215–221. doi: 10.1016/s0014-2964(73)80021-0. [DOI] [PubMed] [Google Scholar]
  15. Wozniak A. J., Glisson B. S., Hande K. R., Ross W. E. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res. 1984 Feb;44(2):626–632. [PubMed] [Google Scholar]
  16. Wozniak A. J., Ross W. E. DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res. 1983 Jan;43(1):120–124. [PubMed] [Google Scholar]
  17. Yalowich J. C., Ross W. E. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res. 1984 Aug;44(8):3360–3365. [PubMed] [Google Scholar]
  18. van Maanen J. M., Lafleur M. V., Mans D. R., van den Akker E., de Ruiter C., Kootstra P. R., Pappie D., de Vries J., Retèl J., Pinedo H. M. Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded phi X174 DNA. Biochem Pharmacol. 1988 Oct 1;37(19):3579–3589. doi: 10.1016/0006-2952(88)90388-7. [DOI] [PubMed] [Google Scholar]
  19. van Maanen J. M., Retèl J., de Vries J., Pinedo H. M. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst. 1988 Dec 7;80(19):1526–1533. doi: 10.1093/jnci/80.19.1526. [DOI] [PubMed] [Google Scholar]
  20. van Maanen J. M., Verkerk U. H., Broersen J., Lafleur M. V., De Vries J., Retèl J., Pinedo H. M. Semi-quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Radic Res Commun. 1988;4(6):371–384. doi: 10.3109/10715768809066905. [DOI] [PubMed] [Google Scholar]
  21. van Maanen J. M., de Ruiter C., Kootstra P. R., Lafleur M. V., de Vries J., Retèl J., Pinedo H. M. Inactivation of phi X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1215–1218. doi: 10.1016/0277-5379(85)90018-5. [DOI] [PubMed] [Google Scholar]
  22. van Maanen J. M., de Vries J., Pappie D., van den Akker E., Lafleur V. M., Retèl J., van der Greef J., Pinedo H. M. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res. 1987 Sep 1;47(17):4658–4662. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES